Our Experties..

Press View

Press View database covers global pharmaceutical and biotech companies daily announcements on drug development and corporate updates.

Database covers more than 4,500 active companies that includes development and commercial drugs companies.

  • Currently covers more than 22,000 press releases from 2016 to till date
  • Key features are Drug Name, Company Name, Event Type, Deal Value, Future Date, Future Date Event and Drug Nature
  • Graphical view by Event Type, Trial Events, Development Stage and Disease Area
  • Export data option to view and client can create customized data templates

Customized support for the below data fields,

  • Drug unique features NME, First-in-Class and Regulatory Designations
  • Latest peer reviewed journals from ASCO, NEJM, ESMO, and ASH
  • Historical Drug Sales and Patents

R&DTrend View

Provides comprehensive analysis on drug research and market innovations with key data attributes.

Drug research expenses and success rates depends on molecule type and indication,

  • New molecule or therapy innovations are highly challenging and very expensive
  • New delivery or enhancements to the new molecule innovations are less time consuming and cost effective
  • Generic or Biosimilar drug development is alternate therapy to the expensive therapy

Trend analysis covers detailed information on Companies, Drugs, Patents and Sales. Topics covered in the database are,

  • Extended Release Drugs
  • 505b2 Drugs
  • NME Drug Approvals from 2000-2019

Future topics,

  • AAV based Pipeline Drugs
  • siRNA Approved and Pipeline Drugs
  • Antibody-drug conjugates or ADCs
  • Early stage Biologic Drugs
  • PDUFA drugs

Latest News

Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

Latest News

Basilea announces positive results from the Phase 3 TARGET study of the antibiotic ceftobiprole for the treatment of acute bacterial skin and soft tissue infections (ABSSSI)

Sanofi: Dupixent® (dupilumab) has shown positive phase III results in the treatment of severe atopic dermatitis in children aged 6 to 11 years